Clinical Trials Register

Summary
EudraCT Number:	2021-001693-33
Sponsor's Protocol Code Number:	ITL-2002-CL-001
National Competent Authority:	Spain - AEMPS
Clinical Trial Type:	EEA CTA
Trial Status:	Prematurely Ended
Date on which this record was first entered in the EudraCT database:	2023-02-14
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

Spain - AEMPS

A.2

EudraCT number

2021-001693-33

A.3

Full title of the trial

Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A Study to Evaluate NTLA-2002 in adults with Hereditary Angioedema (HAE)

A.4.1

Sponsor's protocol code number

ITL-2002-CL-001

A.5.4

Other Identifiers

Name:

ClinicalTrials.gov Number

Number:

NCT05120830

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	Intellia Therapeutics, Inc.
B.1.3.4	Country	United States
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	Intellia Therapeutics, Inc.
B.4.2	Country	United States
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	Intellia Therapeutics Inc
B.5.2	Functional name of contact point	Clinical Program Management
B.5.3	Address:
B.5.3.1	Street Address	40 Erie St,
B.5.3.2	Town/ city	Cambridge,
B.5.3.3	Post code	MA 02139
B.5.3.4	Country	United States
B.5.6	E-mail	ITL-2002-CL-001_clinical@intelliatx.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	NTLA-2002
D.3.2	Product code	NTLA-2002
D.3.4	Pharmaceutical form	Solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	not yet assigned
D.3.9.2	Current sponsor code	mRNA000042
D.3.9.3	Other descriptive name	Messenger RNA encoding Cas9
D.3.9.4	EV Substance Code	SUB215819
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	1.0
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	not yet assigned
D.3.9.2	Current sponsor code	hu-G012267
D.3.9.4	EV Substance Code	SUB233496
D.3.10	Strength
D.3.10.1	Concentration unit	mg/ml milligram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	0.5
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	Yes
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	Yes
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo
D.8 Placebo: 1
D.8.1	Is a Placebo used in this Trial?	Yes
D.8.3	Pharmaceutical form of the placebo	Solution for infusion
D.8.4	Route of administration of the placebo	Intravenous use

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

Hereditary Angioedema

E.1.1.1

Medical condition in easily understood language

Hereditary Angioedema is a genetic condition characterised by swelling of tissues. These swellings can occur on any part of the body.

E.1.1.2

Therapeutic area

Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

MedDRA Classification

E.1.2 Medical condition or disease under investigation

E.1.2	Version	23.1
E.1.2	Level	PT
E.1.2	Classification code	10019860
E.1.2	Term	Hereditary angioedema
E.1.2	System Organ Class	10010331 - Congenital, familial and genetic disorders

E.1.3

Condition being studied is a rare disease

Yes

E.2 Objective of the trial

E.2.1

Main objective of the trial

Phase 1: Primary Objective - To evaluate the safety of NTLA-2002 and identify dose(s) for use in Phase 2
Phase 2: Primary Objective - To evaluate the effect of NTLA-2002 on HAE attacks

E.2.2

Secondary objectives of the trial

Phase 1: Secondary Objectives - To evaluate the pharmacodynamics of NTLA-2002;
- To evaluate the PD of NTLA-2002
- To evaluate the PK of NTLA-2002
Phase 2: Secondary Objectives - To evaluate the safety of selected dose(s) of NTLA-2002 ;
- To evaluate alternate measures of the effect of NTLA-2002 on HAE attacks
- To evaluate the PD of NTLA-2002
- To evaluate the PK of NTLA-2002

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. Subjects ≥ 18 years of age at the time of signing the informed consent.
2. Documented diagnosis of HAE (Type I or II) confirmed by laboratory assessment of functional C1-INH level and C1-INH concentration:
a. For HAE Type I: Both functional C1-INH level AND C1-INH concentration should be <50% of normal limits (or per local standard)
b. For HAE Type II: Functional C1-INH level should be <50% of normal limits (or per local standard). C1-INH concentration may be normal or
above normal.
C1-INH testing during screening, at either the central or an accredited local laboratory, or previously documented results from an accredited
local laboratory may be used to confirm eligibility. If frequent use of C1- INH for the prevention or treatment of HAE attacks would confound
interpretation of C1-INH testing, genetic testing for known variants in the SERPING1 gene in a local laboratory may be used to confirm
eligibility upon consultation with the Sponsor.
3. Investigator-confirmed attacks (per Appendix 3 in Section 10.3):
a. Phase 1 only: Subjects must have an Investigator-confirmed and documented historical HAE attack number of at least 3 during the
previous 3 months (90 days) from the start of screening.
b. Phase 2 only: Subjects must have an Investigator-confirmed and documented historical HAE attack number of at least 3 during the
previous 3 months (90 days) to enter the Screening/Run-In period and an Investigator-confirmed and documented HAE attacks number of at
least 2 during the up to 8-week (up to 56-day) Screening/Run-In period (or at least 3 to be eligible for early enrollment and randomization).
c. Netherlands only: For both Phase 1 and Phase 2, subjects must have had inadequate control of HAE attacks, as determined by the
Investigator, while receiving at least one prior prophylactic regimen, or have required discontinuation from, or otherwise be ineligible for,
available prophylactic agents.
4. Phase 2 only: Subjects must agree to refrain from the use of prophylactic therapies from within 5 half-lives prior to the start of the
Screening/Run-In period through the end of the 16-week primary observation period, and the Investigator must confirm that this is
medically appropriate and does not place the subject at undue safety risk. See Section 10.2 for a list of prophylaxis agents, half-lives, and
recommended wash-out period.
5. Subjects must have access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks.
6. Subjects must meet the following laboratory criteria during Screening:
a. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and total bilirubin (see exception for Gilbert's Syndrome below) ≤ upper
limit of normal (ULN) range at Screening.
b. For subjects with a history of Gilbert's Syndrome, total bilirubin ≤ 2 × ULN on screening evaluation.
c. Serum creatinine is ≤ ULN, or, for subjects in whom serum creatinine is above the ULN, they can be included if the estimated glomerular
filtration rate (eGFR) is > 60 mL/min/1.73 m2 as measured by the Modification of Diet in Renal Disease equation at Screening.
d. Platelet count ≥ 100,000 cells/mm3 at Screening.
e. Within reference range or Principal Investigator (PI)-determined clinically non-significant activated partial thromboplastin time (aPTT),
international normalized ratio (INR), fibrinogen and d-dimer levels at Screening.
7. Male subjects with partners of childbearing potential must agree to using a condom as of the date of informed consent and for 4 months
after study drug administration.
8. Male subjects must agree not to donate sperm for 4 months after study drug administration. The time frame may be extended beyond the
4 months if sperm donation is contraindicated based on country-specific guidelines.
9. Female subjects of childbearing potential must agree to use a protocol-specified highly effective method of contraception (see Section
10.5) from completion of the informed consent process through 12 months after the last studydrug administration. This is not required of
female subjects who are either:
a. Postmenopausal (defined as no menses for 12 months without an alternative medical cause) prior to Screening. In addition, at least 2 high follicle stimulating hormone (FSH) measurements in the postmenopausal range may be used to confirm a postmenopausal state in women with less than 12 months of amenorrhea and not using hormonal contraception or hormonal replacement therapy; OR
b. Surgically sterile (i.e., hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) at least 1 month prior to Screening.
10. Subjects must agree not to participate in another interventional study for the duration of this trial.
11. Subjects must be capable of providing signed informed consent.
12. France only: Adults subjects under guardianship are not considered able to provide informed consent.

E.4

Principal exclusion criteria

1. Use of ecallantide from 1 week prior to the start of Screening through the 16-week primary observation period.
2. Use of C1 esterase inhibitor (C1-INH) for HAE within 5 half-lives of the agent before initiation of the Phase 2 Screening/Run-In period, i.e., 24-
hour washout is required before starting the Screening/Run-In period after the use of rabbit purified C1-INH (ruconest), and 4-day washout is
required before starting the Screening/Run-In period after the use of human plasma purified C1-INH (berinert). Note: during the
Screening/Run-In period, C1-INH may be used to treat an acute HAE attack.
3. Concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema.
4. Subjects who have known hypersensitivity to any lipid nanoparticles (LNP) component (or its excipients) or who have previously received
LNP and experienced any treatment-related clinically significant laboratory abnormalities or AEs listed below:
a. ALT or AST > 3 × ULN if baseline was normal or > 3 × baseline if baseline was above normal.
b. INR, aPTT or d-dimer > 1.5 × ULN if baseline was normal or > 1.5 × baseline if baseline was above normal.
c. Any LNP treatment-related AEs classified as CTCAE Grade 3 or higher.
d. Infusion-related reaction (IRR) to an LNP-containing product (or excipients) requiring treatment or discontinuation of infusion; NOTE:
slowing of the infusion rate to mitigate an IRR is not considered exclusionary.
e. Any LNP treatment-related AEs which in the opinion of the Investigator should be exclusionary.
5. Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption within 90
days prior to study drug administration.
6. Unable or unwilling to take the required pre-treatment medication regimen.
7. Female subjects of childbearing potential are excluded from the study if they:
a. are breastfeeding or plan to breastfeed during treatment and for an additional 12 months after the last study drug administration.
b. have a positive pregnancy test at screening and/or Day 1.
8. Antithrombotic therapy other than aspirin (e.g., warfarin, dabigatran, apixaban) within 14 days prior to study drug administration.
9. History of thrombophilia, or positive genetic test for Factor V Leiden and/or prothrombin 20210.
10. History of cirrhosis.
11. Known or suspected systemic viral, parasitic, or fungal infection including coronavirus disease (COVID-19) or received antibiotics for
bacterial infection within 14 days prior to Screening.
12. History of Hepatitis B or C infection or positive Hepatitis B surface antigen (HbsAg) or Hepatitis C virus antibody (HCVAb) test at Screening.
13. History of positive human immunodeficiency virus (HIV) status.
14. Prior liver, heart, or other solid organ transplant or bone marrow transplant or anticipated transplant within 1 year of Screening. Note: prior history of or planned corneal transplant is not exclusionary.
15. Subject has a history of alcohol or drug abuse within 3 years prior to Screening.
16. Any condition, laboratory abnormality, psycho-social stressor, pattern of behavior, or other reason that, in the Investigator's opinion,
could adversely affect the safety of the subject, impair the assessment of study results, or preclude compliance with the study.
17. Unwilling to comply with study procedures including follow-up as specified by the protocol or unwilling to cooperate fully with the
Investigator.

E.5 End points

E.5.1

Primary end point(s)

Phase 1: Primary Endpoint:
- Safety and tolerability as determined by adverse events (AEs)
- Dose-limiting toxicities (DLTs)

Phase 2:
- Number of HAE attacks per month

E.5.1.1

Timepoint(s) of evaluation of this end point

Phase 1: Primary Endpoint: from Day 1 (post dose) through week 16

Phase 2: Primary Endpoint: from Baseline through week 16

E.5.2

Secondary end point(s)

Phase 1: Secondary Endpoints:
- Change from baseline in total plasma prekallikrein/kallikrein protein level
- Plasma and urine concentrations for DMG PEG2k, LP000001, clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) messenger ribonucleic acid (mRNA), and single guide RNA (sgRNA)

Phase 2 - secondary endpoints
- Safety and tolerability as determined by AEs
- Number of HAE attacks rate per month (by HAE Attack
Assessment and Reporting Procedure – see Section 10.3) (Weeks 5 to 16) and number of HAE attacks requiring acute therapy per month (Weeks 1 to 16, Weeks 5 to 16)
Number of moderate or severe HAE attacks per months (weeks 5 to 16)
- Change from baseline in total plasma prekallikrein/kallikrein protein level
- Plasma and urine concentrations for DMG-PEG2k, LP000001, Cas9 mRNA, and sgRNA

E.5.2.1

Timepoint(s) of evaluation of this end point

Phase 1: Secondary Endpoints:
(Weeks 1-16, Weeks 5-16)
change from baseline

Phase 2: Secondary Endpoints
- (Weeks 1-16, Weeks 5-16)
change from baseline

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

Yes

E.6.3

Therapy

Yes

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

Yes

E.6.8

Bioequivalence

E.6.9

Dose response

Yes

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

Yes

E.7.1.1

First administration to humans

Yes

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

Yes

E.8.1.1

Randomised

Yes

E.8.1.2

Open

E.8.1.3

Single blind

E.8.1.4

Double blind

Yes

E.8.1.5

Parallel group

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

E.8.2.2

Placebo

Yes

E.8.2.3

Other

E.8.2.4

Number of treatment arms in the trial

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Australia

Canada

New Zealand

United States

France

Netherlands

Spain

Germany

United Kingdom

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LVLS

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

F.1.3

Elderly (>=65 years)

Yes

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None

G. Investigator Networks to be involved in the Trial

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2023-07-03

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2023-05-08

P. End of Trial
P.	End of Trial Status	Prematurely Ended

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials